Phytochemcial analysis coupling with network pharmacology analyses identify key targets of DXR for treating MASH, including AKT1, EGFR, TP53, STAT3, and IL6, with biological processes related to oxidative stress. This evidence concerns the gene AKT1 and metabolic dysfunction-associated steatohepatitis.